S-Adenosyl-Methionine
PreclinicalSmall molecule
S-Adenosyl-Methionine is one of 20 small molecule programs targeting Abdominal pain. It is currently in Preclinical.
2
Indications
5
Total Trials
0
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
19 competitors in Abdominal Pain
#DrugCompanyPhaseTrials
1Elavil
AstraZenecaApproved
Niacor
AbbVieApproved
Lopid
PfizerApproved
Dilaudid
RRhodes Pharmaceuticals, L.P.
Approved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Proair HFA
GGlaxo Dba Glaxosmithkline
Approved
Marcaine
IInnocoll
Approved
Naropin
FFresenius Kabi USA, LLC
Approved
Kenalog
BBassett Healthcare
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hepatocellular Carcinoma2 trials
Cirrhosis1 trial
SAMe to Treat Biliary Cirrhosis Symptoms
Terminated·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00125281·50 enrolled
Abdominal pain1 trial
Evaluation of S-adenosyl Methionine (SAM-e) for Recurrent Abdominal Pain in Children
Completed·—·N/A·NCT00694564·8 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for S-Adenosyl-Methionine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details